BioWorld

Aug. 17, 2009

Split Panel Vote Takes Shine off Denosumab: Is PMO Only So-So?

As the dust settled following Thursday's messy panel vote, Amgen Inc.'s much-touted bone drug looked a bit worse for wear. (BioWorld Today) Read More

Clinical Data Driving Biotech's Rebound So Far, BIO Reports

New Evidence for Autoimmunity Connection to Psych Disorders

NewCo News: Treventis has Multiple Targets as It Focuses on Alzheimer's

AGI Loses Axcan as Partner on GERD Drug Omeprazole

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 17, 2026